Due to the risk of overdiagnosis and overtreatment on the one hand and lack of clinically significant localized PC eligible for curative treatment on the other hand, the use of prostate specific antigen (PSA) as a marker for early detection must be chosen wisely and recommendations differ between guidelines [2, 40, 51]. This evidence concerns the gene KLK3 and pachyonychia congenita.